Editorial Material
Oncology
Shelley Kuang, Natasha B. Leighl
Summary: The study in NEJM examined whether lorlatinib should be the standard first-line treatment for advanced ALK-rearranged lung cancer.
Article
Cell Biology
Xiaona Xie, Xueding Cai, Yemeng Tang, Chunhui Jiang, Feng Zhou, Lehe Yang, Zhiguo Liu, Liangxing Wang, Haiyang Zhao, Chengguang Zhao, Xiaoying Huang
Summary: Flubendazole, a traditional anthelmintic drug, exhibits potent antitumor activity in non-small cell lung carcinoma (NSCLC) by suppressing STAT3 activity and activating autophagy. It has the potential to be a new therapeutic agent for NSCLC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Naohiro Yanagimura, Shinji Takeuchi, Koji Fukuda, Sachiko Arai, Azusa Tanimoto, Akihiro Nishiyama, Naohisa Ogo, Hiroyuki Takahashi, Akira Asai, Satoshi Watanabe, Toshiaki Kikuchi, Seiji Yano
Summary: This study investigated new therapeutic strategies to reduce and eliminate residual tumors in the early treatment phase of ALK-rearranged lung cancer. It found that the adaptive survival of these cancer cells was predominantly dependent on STAT3 activity upon ALK inhibition, and inhibition of STAT3 effectively suppressed their survival. The combination of a STAT3 inhibitor and alectinib significantly suppressed tumor regrowth after treatment cessation.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Sameera Kumar, Xiaoliang Wang, Harlan Pittell, Gregory S. Calip, Stephanie E. Weiss, Joshua E. Meyer, Trevor J. Royce
Summary: This study investigated the use of CNS-Directed RT in NSCLC patients on first-line ALK inhibitors and found a decreasing trend. The findings suggest that physicians may be deferring upfront local therapy for BM in favor of novel targeted agents with improved CNS activity.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Rafal Dziadziuszko, Matthew G. Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Anna F. Farago, Chia-Chi Lin, Christos S. Karapetis, Yu-Chung Li, Bann-mo Day, David Chen, Timothy R. Wilson, Fabrice Barlesi
Summary: Entrectinib continues to show a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including those with central nervous system metastases.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Dara L. Aisner, Gregory J. Riely
Summary: The 2021 updates to the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) emphasize the importance of biomarker testing for newly diagnosed advanced lung cancer patients and recommend targeted first-line therapies based on genetic alterations. Additionally, adjuvant treatment with osimertinib for resected early-stage EGFR-mutated NSCLC is highlighted. New recommendations include targeted agents for ALK rearrangements, RET alterations, MET exon 14 skipping mutations in advanced NSCLC, as well as immunotherapy agents for advanced NSCLC without a driver oncogene.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Multidisciplinary Sciences
Anna M. Schlafli, Igor Tokarchuk, Sarah Parejo, Susanne Jutzi, Sabina Berezowska, Nikolai Engedal, Mario P. Tschan
Summary: The study shows that ALK inhibition induces LC3B-independent macroautophagic flux in EML4-ALK(+) cells to support cancer cell survival and clonogenic growth.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Chunfeng Xie, Xu Zhou, Chunhua Liang, Xiaoting Li, Miaomiao Ge, Yue Chen, Juan Yin, Jianyun Zhu, Caiyun Zhong
Summary: Apatinib inhibits cell proliferation and promotes apoptosis in non-small cell lung cancer cells through modulation of various signaling pathways. It suppresses malignant and stem-like features of cancer cells and induces autophagy and apoptotic cell death. Additionally, apatinib shows promising effects in inhibiting tumor growth in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Shun Lu, Hongming Pan, Lin Wu, Yu Yao, Jianxing He, Yan Wang, Xiuwen Wang, Yong Fang, Zhen Zhou, Xicheng Wang, Xiuyu Cai, Yan Yu, Zhiyong Ma, Xuhong Min, Zhixiong Yang, Lejie Cao, Huaping Yang, Yongqian Shu, Wu Zhuang, Shundong Cang, Jian Fang, Kai Li, Zhuang Yu, Jiuwei Cui, Yang Zhang, Man Li, Xinxuan Wen, Jie Zhang, Weidong Li, Jianhua Shi, Xingxiang Xu, Diansheng Zhong, Tao Wang, Jiajia Zhu
Summary: This phase I/II trial evaluated the tolerability, safety, and antitumor activities of unecritinib in advanced tumors and ROS1 inhibitor-naive advanced or metastatic NSCLC. The ORR in phase I trial was 63.9%, while in phase II trial, the ORR was 80.2% and the median PFS was 16.5 months. Unecritinib demonstrated efficacy and safety as a treatment option for ROS1-positive NSCLC, particularly in patients with brain metastases at baseline.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Multidisciplinary Sciences
Ha-Young Seo, Soon-Chan Kim, Woo-lee Roh, Young-Kyoung Shin, Soyeon Kim, Dong-Wan Kim, Tae Min Kim, Ja-Lok Ku
Summary: Malignant pleural effusion (MPE) is a crucial factor in the poor prognosis of non-small cell lung cancer (NSCLC). By analyzing genomic, transcriptomic, and pharmacologic data from MPE-derived NSCLC cell lines, this study found that these cell lines exhibit driver gene mutations and distinct translational subtypes. The drug responses of these cell lines also align with their genomic and transcriptomic characteristics.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Arlou Kristina Angeles, Petros Christopoulos, Zhao Yuan, Simone Bauer, Florian Janke, Simon John Ogrodnik, Martin Reck, Matthias Schlesner, Michael Meister, Marc A. Schneider, Steffen Dietz, Albrecht Stenzinger, Michael Thomas, Holger Sultmann
Summary: This study utilized various sequencing technologies to analyze plasma DNA from 43 ALK+ NSCLC patients receiving ALK-directed therapies, finding that 51% of these patients had ALK-related alterations. Evidence for early detection of disease progression is crucial for guiding patient management and therapy decisions.
NPJ PRECISION ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Bin Wang, Yang Song, Zhuo Chen, Xiaona Su, Xin Yang, Zhi Wei, Junxia Chen, Chuan Chen, Mengxia Li
Summary: This study aimed to investigate the therapeutic effect and safety of ALK inhibitor in ALK-positive lung cancer patients. A total of 59 patients were recruited and divided into two groups: conventional adjuvant chemotherapy and targeted therapy with crizotinib. The results showed that targeted therapy significantly improved disease-free survival (DFS) and overall survival (OS) compared to adjuvant chemotherapy (P < 0.05). Elevated aspartate transaminase/alanine aminotransferase, nausea, and vomiting were the most common adverse events observed.
SCIENTIFIC REPORTS
(2023)
Article
Pharmacology & Pharmacy
Yuanteng Zhang, Zizheng Gao, Zezheng Pan, Huangxi Fu, Feng Jiang, Hao Yan, Bo Yang, Qiaojun He, Peihua Luo, Zhifei Xu, Xiaochun Yang
Summary: This study revealed that crizotinib can cause interstitial lung disease and induce apoptosis of alveolar epithelial cells by blocking autophagic flux. It also found that metformin can reduce macrophage recruitment and pulmonary fibrosis by recovering autophagy flux, thereby improving lung damage caused by crizotinib.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Oncology
Moritz Glaser, Anna Rasokat, Darinka Prang, Lucia Nogova, Claudia Woempner, Jaqueline Schmitz, Elisabeth Bitter, Inken Terjung, Anna Eisert, Rieke Fischer, Felix John, Cornelia von Levetzow, Sebastian Michels, Richard Riedel, Lea Ruge, Heather Scharpenseel, Udo Siebolts, Sabine Merkelbach-Bruse, Reinhard Buettner, Johannes Braegelmann, Juergen Wolf, Matthias Scheffler
Summary: In this study, we explored the clinical and molecular characteristics of small-scale ROS1 mutations in NSCLC patients without ROS1 fusions or SFMs. We found that approximately 1.0% of patients harbored small-scale ROS1 mutations. Compared to ROS1-fused patients, co-occurrence of KRAS mutations led to shorter survival and immune-checkpoint blockade therapy was beneficial for patients.
Article
Medicine, General & Internal
Huixian Zhang, Xingya Li, Ziheng Zhang, Siyuan Huang, Qianqian Guo, Ningning Yan
Summary: This study explored the efficacy and safety of ceritinib as a first-line treatment for crizotinib-resistant ROS1-rearranged NSCLC. The results revealed that ceritinib can be a treatment option for ROS1-rearranged NSCLC patients after the development of crizotinib resistance.